The Lynx Group

Abemaciclib, Ribociclib, or Palbociclib for HR+ Metastatic Breast Cancer?

Videos — January 10, 2018

Featuring:

Dr Matthew Goetz reviews what differentiates abemaciclib, the latest CDK4/6 inhibitor FDA approved for HR+ metastatic breast cancer, from ribociclib and palbociclib.

Related Articles

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: